Clinical trials: Interferon Alpha
Chronic Hepatitis C
Albinterferon Alfa 2b Single Dose in Japanese Chronic Hepatitis C Patients
This study will evaluate safety, tolerability, pharmacokinetics and pharmacodynamics of albinterferon alfa 2b (alb-IFN) single dose in Japanese chronic hepatitis C patients
- Trial name
- NCT00724776
- Testing
- Albinterferon alfa 2b
- Where
- Japan
- Volunteers
- 30 people
- Sponsor
- Novartis
HIV, HIV/AIDS
Peg-Interferon Alpha 2b Combined With Two Intravenous Broadly HIV-1 Neutralizing Antibodies 3BNC117 and 10-1074 (BEAT-2)
This study will evaluate the safety, tolerability and innate immune mechanisms activation following administration of the combination of Pegylated Interferon alpha 2b (peg-IFN-α2b) with two broadly neutralizing antibodies…
- Conditions
- HIV, HIV/AIDS, HIV-1 Infection
- Trial name
- BEAT-2 (NCT03588715)
- Testing
- Pegylated Interferon alpha 2b (peg-IFN-α2b), 3BNC117 + 10-1074
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- Luis Montaner
Carcinoma, Renal Cell
SU011248 Versus Interferon-Alfa As First-Line Systemic Therapy For Patients With Metastatic Renal Cell Carcinoma
The purpose of this study is to test whether SU011248 has activity and is safe compared to interferon-alfa as first-line therapy in patients with metastatic renal cell carcinoma (RCC).
- Trial name
- NCT00083889
- Testing
- Interferon-alfa, SU011248
- Where
- 123 sites in United States, Australia and 9 more
- Volunteers
- 750 people
- Sponsor
- Pfizer
Chronic Hepatitis c, Insulin Resistance
Effects of Metformin, Pegylated Interferon Alpha and Ribavirin for Chronic Hepatitis C With Insulin Resistance
The aim of the study is to investigate the treatment response of metformin, Peg-IFN and ribavirin combination therapy for chronic hepatitis C virus (HCV).
- Trial name
- NCT01664845
- Testing
- metformin, pegylated-IFN, ribavirin
- Where
- Taiwan
- Volunteers
- 120 people
- Sponsor
- Kaohsiung Veterans General Hospital.
Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma
Rintatolimod, Celecoxib and Interferon Alpha 2b With Pembrolizumab For the Treatment of Patients With Metastatic or Unresectable Triple Negative Breast Cancer
This phase I/IIa trial tests the safety, side effects, and best dose of chemokine modulation therapy (CKM) (rintatolimod, celecoxib, and interferon alpha 2b) in combination with pembrolizumab for the treatment of patients with…
- Conditions
- Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma, Unresectable Triple-Negative Breast Carcinoma
- Trial name
- NCT05756166
- Testing
- Biopsy, Biospecimen Collection, Celecoxib
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Roswell Park Cancer Institute
HIV Infections
A Randomized, Dose-ranging Study of Alferon LDO in Asymptomatic HIV+ Subjects
To conduct a randomized dose-ranging study to evaluate the safety and activity of orally administered low dose interferon alfa-n3 as an immunomodulator in subjects with asymptomatic HIV-1 infection.
- Trial name
- NCT00215852
- Testing
- Alferon LDO
- Where
- 2 sites in United States
- Volunteers
- 17 people
- Sponsor
- AIM ImmunoTech Inc.
Hepatitis C, Chronic
Antiviral Effect, Safety, and Pharmacokinetics of BI201335 +PegIFN/RBV in HCV-GT1 (SILEN-C1&2)
The objective was to investigate the antiviral effect, safety, and pharmacokinetics of BI 201335 (Faldaprevir), given as a soft gelatine capsule, in patients with hepatitis C virus (HCV) genotype 1 infection.
- Trial name
- NCT00774397
- Testing
- BI 201335 NA 240 mg QD / LI, PegIFN/RBV, BI 201335 NA 120mg QD / LI
- Where
- 100 sites in United States, Argentina and 13 more
- Volunteers
- 719 people
- Sponsor
- Boehringer Ingelheim
Leukemia
Imatinib Mesylate With or Without Interferon Alfa or Cytarabine Compared With Interferon Alfa Followed by Donor Stem Cell Transplant in Treating Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia
RATIONALE: Giving chemotherapy before a donor bone marrow transplant helps stop the growth of cancer cells. It also helps stop the patient's immune system from rejecting the donor's stem cells.
- Trial name
- NCT00055874
- Testing
- recombinant interferon alfa, cytarabine, hydroxyurea
- Where
- 66 sites in Germany, Switzerland
- Volunteers
- 1,551 people
- Sponsor
- Heidelberg University
Carcinoma of Urinary Bladder, Superficial
Combined Use of BCG and Interferon Alpha in Bladder Cancer
To compare the toxicity and efficacy of the combination of BCG and interferon alpha to standard dose and low dose BCG alone in high risk superficial bladder cancer
- Trial name
- NCT00330707
- Testing
- Bacillus Calmette Guerin and interferon alpha
- Where
- Singapore
- Volunteers
- 140 people
- Sponsor
- National University Hospital, Singapore
Polycythemia Vera
Safety Study of Pegylated Interferon Alpha 2b to Treat Polycythemia Vera
The purpose of this study is the identification of the maximum tolerated dose (MTD) of the investigational medicinal product. Moreover the safety and tolerability will be assessed and an exploratory analysis of efficacy and…
- Trial name
- PEGINVERA (NCT01193699)
- Testing
- PEG-P-INF alpha-2b (P1101)
- Where
- 6 sites in Austria
- Volunteers
- 24 people
- Sponsor
- AOP Orphan Pharmaceuticals AG
Systemic Lupus Erythematosus
A Study to Evaluate Safety and Tolerability of IV or SC Dose of MEDI-545 in Patients With Systemic Lupus Erythematosus.
The purpose of the study is to evaluate the safety and tolerability of MEDI-545 in Japanese adult SLE patients. This will be done by collecting the data from 3 cohorts of IV doses and 1 cohort of SC doses.
- Trial name
- NCT01031836
- Testing
- MEDI-545, MEDI-545 600
- Where
- 7 sites in Japan
- Volunteers
- 30 people
- Sponsor
- AstraZeneca
Lymphoma
S9805, High-Dose Melphalan Plus Peripheral Stem Cell Transplantation Followed by Interferon Alfa in Treating Patients With Waldenstrom's Macroglobulinemia
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of…
- Trial name
- NCT00003416
- Testing
- filgrastim, recombinant interferon alfa, dexamethasone
- Where
- 84 sites in United States
- Volunteers
- 9 people
- Sponsor
- SWOG Cancer Research Network
Adenocarcinoma Clear Cell
Immunochemotherapy for Metastatic Renal Cell Carcinoma
Immunochemotherapy consisting of IL-2, INF-A, and VBL and 5FU is regarded as the treatment of choice in metastatic renal cell carcinoma.
- Trial name
- NCT00226798
- Testing
- Capecitabine (Xeloda)
- Where
- Israel
- Volunteers
- 45 people
- Sponsor
- Rambam Health Care Campus
Leukemia
Chemotherapy Followed by Peripheral Stem Cell Transplantation And Biological Therapy in Treating Patients With Chronic Myelogenous Leukemia
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Biological therapies use different ways to stimulate the immune system and stop cancer cells from growing.
- Trial name
- NCT00005948
- Testing
- aldesleukin, recombinant interferon alfa, sargramostim
- Where
- 2 sites in United States
- Sponsor
- Fred Hutchinson Cancer Center
Hepatitis C, Genotype 3
Interferon-gamma With Interferon Alpha and Ribavirin for Hepatitis C Non-responders
When administered simultaneously, interferon-alpha 2b + interferon-gamma result in dramatic antiviral synergy.Ribavirin has shown to enhance interferon-gamma levels in patients with chronic hepatitis C treated with…
- Conditions
- Hepatitis C, Genotype 3, Non-responders, Relapsers
- Trial name
- NCT00538811
- Testing
- interferon alpha-2b, ribavirin, interferon-gamma,, interferon alpha-2b, ribavirin, amantadine
- Where
- 2 sites in Pakistan
- Volunteers
- 40 people
- Sponsor
- Aga Khan University
Melanoma (Skin)
High-Dose or Low-Dose Interferon Alfa Compared With No Further Therapy Following Surgery in Treating Patients With Stage III Melanoma
RATIONALE: Interferon alfa may interfere with the growth of cancer cells. It is not known whether giving high-dose or low-dose interferon alfa is more effective than no further therapy in treating patients with stage III…
- Trial name
- NCT00002763
- Testing
- recombinant interferon alfa
- Where
- 86 sites in Austria, Belgium and 19 more
- Volunteers
- 1,000 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Leukemia
Imatinib Mesylate and Interferon Alfa in Treating Patients With Chronic Myelogenous Leukemia
RATIONALE: Imatinib mesylate and interferon alfa may interfere with the growth of the cancer cells. Combining imatinib mesylate with interferon alfa may kill more cancer cells.
- Trial name
- NCT00015847
- Testing
- recombinant interferon alfa, imatinib mesylate
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- OHSU Knight Cancer Institute
Hepatitis C, Chronic
Dose Finding Study of Pegylated-P-Interferon-alpha-2b(P1101) in Treatment-Naive Subjects With Hepatitis C Virus Genotype 1 Infection
Primary objectives: The purpose of this study is to determine and compare the sustained virologic response (SVR, undetectable HCV RNA at Follow up week 24 (FW24)) across treatment groups.
- Trial name
- NCT01587586
- Testing
- PEGASYS 180 µg Q1W, P1101 180 µg Q1W, 48 doses, P1101 270µg Q1W, 48 doses
- Where
- 13 sites in Taiwan
- Volunteers
- 107 people
- Sponsor
- PharmaEssentia
Chronic Hepatitis C, Hemodialysis
Retreatment of Dialysis Patients With Chronic Hepatitis C With Pegylated Interferon Alfa-2a Plus Low Dose Ribavirin
Chronic hepatitis C virus (HCV) infection is common in dialysis patients. Interferon (IFN)-based treatment for chronic hepatitis C has been the mainstay therapy in immunocompetent patients.
- Trial name
- NCT00491179
- Testing
- Pegylated interferon alfa-2a and ribavirin
- Where
- Taiwan
- Volunteers
- 35 people
- Sponsor
- National Taiwan University Hospital
Leukemia, Myeloid, Chronic
High-Dose Gleevec Alone or in Combination With Peg-Intron and GM-CSF in Early Phase Chronic Myelogenous Leukemia (CML)
The goal of this clinical research study is to learn if giving PEG-Alpha Interferon (PEG-Intron) and Sargramostim (GM-CSF) to patients receiving treatment with high dose Gleevec (imatinib mesylate) is more effective in treating…
- Trial name
- NCT00050531
- Testing
- Gleevec, Peg-alpha interferon (Peg-Intron), Sargramostim (GM-CSF)
- Where
- United States
- Volunteers
- 94 people
- Sponsor
- M.D. Anderson Cancer Center